When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters was with a 24-year-old patient whose sickle cell disease left them with almost weekly pain episodes.
Risk Adjusted Net Present Value: What is the current valuation of Soleno Therapeutics’s Diazoxide choline CR
The revenue for Diazoxide choline CR is expected to reach an annual total of $729 mn by 2034 in the US based off GlobalDatas Expiry
September 8, 2024